Download PDF
Klin Padiatr 2014; 226(02): 53-58
DOI: 10.1055/s-0033-1363687
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Neonatal Respiratory Insufficiency Caused by an (Homozygous) ABCA3-Stop Mutation: a Systematic Evaluation of Therapeutic Options

Neonatale Ateminsuffizienz durch eine homozygote ABCA3-Stopp-Mutation: systematische Evaluation der Therapieoptionen
J. Winter
1   Neonatology, Children’s Hospital of the University Medical Center of the Johannes Gutenberg University Mainz, Germany
,
S. Essmann
1   Neonatology, Children’s Hospital of the University Medical Center of the Johannes Gutenberg University Mainz, Germany
,
A. Kidszun
1   Neonatology, Children’s Hospital of the University Medical Center of the Johannes Gutenberg University Mainz, Germany
,
C. Aslanidis
2   Institute for Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Germany
,
M. Griese
3   Pediatric Clinic and Policlinic, Dr. von Hauner Children’s Hospital, University Munich, Germany
,
K. Poplawska
4   Pediatric Pulmonology, Children’s Hospital of the University Medical Center of the Johannes ­Gutenberg University Mainz, Germany
,
M. Bartsch
1   Neonatology, Children’s Hospital of the University Medical Center of the Johannes Gutenberg University Mainz, Germany
,
G. Schmitz
2   Institute for Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Germany
,
E. Mildenberger
1   Neonatology, Children’s Hospital of the University Medical Center of the Johannes Gutenberg University Mainz, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
14 March 2014 (online)

Also available at
    Permissions and Reprints

Abstract

Background:

Autosomal recessive ABCA3 (ATP-binding cassette protein A3) gene mutations have been associated with neonatal respiratory distress and pediatric interstitial lung disease. The clinical course of the disease depends on the underlying mutations. Therefore, knowledge of course, symptoms and treatment of the disease is important.

Patient and Methods:

A term newborn suffered from progressive respiratory insufficiency, which led to death at the age of 4.8 months. The girl developed interstitial lung disease. Infections as well as structural and functional disorders of the lung were systematically excluded. A homozygous c.4681C>T (Arg 1561 Stop) mutation of the ABCA3 gene was identified. A literature review of the pathophysiology and treatment options of the disease was done. Therapeutic approaches with corticosteroids, macrolide, and hydroxychloroquine did not improve the clinical course.

Results:

Therapeutic strategies for chronic interstitial lung disease have been used successfully in cases of a mild clinical course in juvenile patients with ABCA3 gene mutation. In our patient with homozygous ABCA3 gene mutation, they were not effective. Lung transplantation remains as a therapeutic option, but because of donor organ shortage and associated morbidity and mortality it is rarely feasible.

Conclusion:

More experience in the treatment of newborns with ABCA3 gene mutations is needed. Randomized, prospective evaluation of the different therapeutic approaches in a specific registry may improve prognosis and treatment of affected individuals.

Zusammenfassung

Hintergrund:

Autosomal rezessiv vererbte ABCA3 (ATP-binding cassette protein A3)-Mu­tationen sind mit schwerem neonatalem Lungenversagen und chronischer interstitieller Lungenerkrankung assoziiert. Der klinische Verlauf der Erkrankung ist stark von den zugrunde liegenden Mutationen abhängig. Aus diesem Grund sind Verlaufsbeschreibungen zu Symptomatik und Therapie wichtig.

Patientin und Methodik:

Ein reifes Neugeborenes litt an einer progredienten respiratorischen Insuffizienz, die im Alter von 4,8 Monaten zum Tod führte. Gleichzeitig entwickelte sich eine interstitielle Lungenerkrankung. Infektionen, funktionelle Störungen und strukturelle Lungenerkrankungen wurden systematisch ausgeschlossen. Ursächlich lag eine homozygote c.4681C>T (Arg 1561 Stop)-Mutation des ABCA3-Gens vor. Eine ausführliche Literaturrecherche zur Pathophysiologie und Therapie der Erkrankung wurde durchgeführt. Therapieversuche mit Corticosteroiden, Makrolid und Hydroxychloroquin erbrachten keine relevante Verbesserung der klinischen Situation.

Ergebnisse:

Die genannten Therapieansätze werden bereits bei Patienten mit ABCA3-Mutationen angewendet und sind bei milden klinischen Verläufen erfolgreich. Bei unserer Patientin mit homozygoter ABCA3-Stopp-Mutation hatten sie keinen Effekt. Die Therapieoption der Lungentransplantation wird im Säuglingsalter wegen Spenderorganmangels und assoziierter Morbidität und Mortalität nur selten realisiert. Nach ausführlicher Evaluation wurde diese Therapiemöglich­keit bei unserer Patientin verworfen.

Schlussfolgerung:

Es besteht Notwendigkeit, mehr Erfahrungen in der Behandlung von Neugeborenen mit ABCA3-Mutationen zu sammeln. Therapieoptionen sollten in einem Patientenregister systematisch erfasst und möglichst randomi­siert prospektiv evaluiert werden, um so Prognose und Betreuung der Patienten zu verbessern.

Key words

ABCA3 gene mutation - neonatal respiratory distress - pediatric interstitial lung disease - medical treatment - lung transplantation

Schlüsselwörter

ABCA3-Mutation - neonatales Lungenversagen - interstitielle Lungenerkrankung bei Kindern - medikamentöse Behandlung - Lungentransplantation
 

  • References

  • 1 Abou Taam R, Jaubert F, Emond S et al. Familial interstitial disease with I73T mutation: A mid- and long-term study. Pediatr Pulmonol 2009; 44: 167-175
    CrossrefPubMedGoogle Scholar
  • 2 Bellini C, Boccardo F, Campisi C et al. Congenital pulmonary lymphangiectasia. Orphanet J Rare Dis 2006; 1: 43
    CrossrefPubMedGoogle Scholar
  • 3 Bishop NB, Stankiewicz P, Steinhorn RH. Alveolar capillary dysplasia. Am J Respir Crit Care Med 2011; 184: 172-179
    CrossrefPubMedGoogle Scholar
  • 4 Brasch F, Schimanski S, Muhlfeld C et al. Alteration of the pulmonary surfactant system in full-term infants with hereditary ABCA3 deficiency. Am J Respir Crit Care Med 2006; 174: 571-580
    CrossrefPubMedGoogle Scholar
  • 5 Bruder E, Hofmeister J, Aslanidis C et al. Ultrastructural and molecular analysis in fatal neonatal interstitial pneumonia caused by a novel ABCA3 mutation. Mod Pathol 2007; 20: 1009-1018
    CrossrefPubMedGoogle Scholar
  • 6 Bullard JE, Wert SE, Nogee LM. ABCA3 deficiency: neonatal respiratory failure and interstitial lung disease. Semin Perinatol 2006; 30: 327-334
    CrossrefPubMedGoogle Scholar
  • 7 Bullard JE, Wert SE, Whitsett JA et al. ABCA3 mutations associated with pediatric interstitial lung disease. Am J Respir Crit Care Med 2005; 172: 1026-1031
    CrossrefPubMedGoogle Scholar
  • 8 Ciantelli M, Ghirri P, Presi S et al. Fatal respiratory failure in a full-term newborn with two ABCA3 gene mutations: a case report. J Perinatol 2011; 31: 70-72
    CrossrefPubMedGoogle Scholar
  • 9 Clement A. Task force on chronic interstitial lung disease in immunocompetent children. Eur Respir J 2004; 24: 686-697
    CrossrefPubMedGoogle Scholar
  • 10 Clement A, Corvol H, Epaud R et al. Dramatic Improvement by Macrolides in Surfactant Deficiency with ABCA3 Mutation. In: San Diego Convention Center: Am J Respir Crit Care Med 2009;
    PubMedGoogle Scholar
  • 11 Clement A, Nathan N, Epaud R et al. Interstitial lung diseases in children. Orphanet J Rare Dis 2010; 5: 22
    CrossrefPubMedGoogle Scholar
  • 12 Deutsch GH, Young LR. Pulmonary interstitial glycogenosis: words of caution. Pediatr Radiol 2010; 40: 1471-1475
    CrossrefPubMedGoogle Scholar
  • 13 Dishop MK. Paediatric interstitial lung disease: classification and definitions. Paediatr Respir Rev 2011; 12: 230-237
    CrossrefPubMedGoogle Scholar
  • 14 Doan ML, Guillerman RP, Dishop MK et al. Clinical, radiological and pathological features of ABCA3 mutations in children. Thorax 2008; 63: 366-373
    CrossrefPubMedGoogle Scholar
  • 15 Faro A, Hamvas A. Lung Transplantation for Inherited Disorders of Surfactant Metabolism. NeoReviews 2008; 9: e468-e476
    CrossrefPubMedGoogle Scholar
  • 16 Flamein F, Riffault L, Muselet-Charlier C et al. Molecular and cellular characteristics of ABCA3 mutations associated with diffuse parenchymal lung diseases in children. Hum Mol Genet 2012; 21: 765-775
    CrossrefPubMedGoogle Scholar
  • 17 Garmany TH, Wambach JA, Heins HB et al. Population and disease-based prevalence of the common mutations associated with surfactant deficiency. Pediatr Res 2008; 63: 645-649
    CrossrefPubMedGoogle Scholar
  • 18 Hamvas A. Evaluation and management of inherited disorders of surfactant metabolism. Chin Med J (Engl) 2010; 123: 2943-2947
    PubMedGoogle Scholar
  • 19 Kaltenborn E, Kern S, Frixel S et al. Respiratory syncytial virus potentiates ABCA3 mutation-induced loss of lung epithelial cell differentiation. Hum Mol Genet 2012; 21: 2793-2806
    CrossrefPubMedGoogle Scholar
  • 20 Kozlik-Feldmann R, Griese M, Netz H et al. Herz- und Lungentransplantation im Kindes- und Jugendalter. Monatsschr Kinderheilkd 2012; 160: 358-376
    CrossrefPubMedGoogle Scholar
  • 21 Matsumura Y, Ban N, Inagaki N. Aberrant catalytic cycle and impaired lipid transport into intracellular vesicles in ABCA3 mutants associated with nonfatal pediatric interstitial lung disease. Am J Physiol Lung Cell Mol Physiol 2008; 295: L698-L707
    CrossrefPubMedGoogle Scholar
  • 22 Matsumura Y, Ban N, Ueda K et al. Characterization and classification of ATP-binding cassette transporter ABCA3 mutants in fatal surfactant deficiency. J Biol Chem 2006; 281: 34503-34514
    CrossrefPubMedGoogle Scholar
  • 23 Palomar LM, Nogee LM, Sweet SC et al. Long-term outcomes after infant lung transplantation for surfactant protein B deficiency related to other causes of respiratory failure. J Pediatr 2006; 149: 548-553
    CrossrefPubMedGoogle Scholar
  • 24 Rosen DM, Waltz DA. Hydroxychloroquine and surfactant protein C deficiency. N Engl J Med 2005; 352: 207-208
    CrossrefPubMedGoogle Scholar
  • 25 Shulenin S, Nogee LM, Annilo T et al. ABCA3 gene mutations in newborns with fatal surfactant deficiency. N Engl J Med 2004; 350: 1296-1303
    CrossrefPubMedGoogle Scholar
  • 26 Thouvenin G, Abou Taam R, Flamein F et al. Characteristics of disorders associated with genetic mutations of surfactant protein C. Arch Dis Child 2010; 95: 449-454
    CrossrefPubMedGoogle Scholar
  • 27 Whitsett JA, Wert SE, Trapnell BC. Genetic disorders influencing lung formation and function at birth. Hum Mol Genet 2004; 13 Spec No 2 R207-R215
    CrossrefPubMedGoogle Scholar
  • 28 Woischnik M, Sparr C, Kern S et al. A non-BRICHOS surfactant protein c mutation disrupts epithelial cell function and intercellular signaling. BMC Cell Biol 2010; 11: 88
    CrossrefPubMedGoogle Scholar
  • 29 Yokota T, Matsumura Y, Ban N et al. Heterozygous ABCA3 mutation associated with non-fatal evolution of respiratory distress. Eur J Pediatr 2008; 167: 691-693
    CrossrefPubMedGoogle Scholar
  • 30 Yoshida I, Ban N, Inagaki N. Expression of ABCA3, a causative gene for fatal surfactant deficiency, is up-regulated by glucocorticoids in lung alveolar type II cells. Biochem Biophys Res Commun 2004; 323: 547-555
    CrossrefPubMedGoogle Scholar